Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford's Professor Sir Peter Ratcliffe has won one of the most prestigious prizes in medicine.

Since 1945, the Lasker Awards has recognised the contributions of scientists, physicians, and public servants who have made major advances in the understanding, diagnosis, treatment, and prevention of human disease. Many past Lasker winners have gone on to be awarded Nobel prizes.

Now, Professor Ratcliffe, is to receive the Albert Lasker Basic Medical Research Award, for his work understanding the mechanisms by which cells sense and signal hypoxia (low oxygen levels). Hypoxia is an important component of many human diseases including cancer, heart disease, stroke, vascular disease, and anaemia.

Read more...

2016 Albert Lasker Basic Medical Research Award

William Kaelin, Peter Ratcliffe, and Gregg Semenza are honored for the discovery of the pathway by which cells from humans and most animals sense and adapt to changes in oxygen availability – a process essential for survival.

2016 Albert Lasker Basic Medical Research Award: Oxygen sensing – an essential process for survival

 

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.